Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

R-Pharm licenses Theravance’s antibiotic programs in CIS region

Executive Summary

Russian finished drug and API manufacturer R-Pharm has licensed exclusive development and commercialization rights in the CIS countries to Theravance Inc.’s Vibativ (telavancin), a lipoglycopeptide for complicated skin and soft tissue infections (cSSSIs) caused by gram-positive bacteria including methicillin-resistant S. aureus (MRSA), and TD1792, a glycopeptide-cephalosporin heterodimer antibiotic candidate.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register